Soligenix, Inc. SNGX 深 滬
交易中 09-05 11:20:51 美东时间
2.91
-0.130
-4.28%
華盛通- 最 高3.07
- 今 開3.07
- 成交量 12.04万股
- 最 低 2.8809
- 昨 收 3.04
- 總市值 949.91万
- 52周最高 6.2299
- 市盈率 靜 --
- 換手率 3.69%
- 52周最低 1.09
- 委 比 33.33%
- 總股本 326.43万
- 歷史最高 1219.20
- 量 比 0.41
- 振 幅 6.22%
- 歷史最低 1.09
- 每 手 1
- 風險率 3.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多'Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years'- Science Direct
https://www.sciencedirect.com/science/article/abs/pii/S0264410X25009818
09-04 02:14
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
08-21 20:24
Watching Soligenix; Zacks Small-Cap Research Gives Stock $35.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08202025_SNGX_Bautz.pdf
08-20 23:00
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
Why Is Soligenix Stock Soaring On Monday?
Soligenix shares surge after FDA granted orphan drug designation to dusquetide for Behçet's Disease, boosting prospects for rare disease treatment.
08-19 01:03
Soligenix Gains FDA Orphan Drug Designation for Dusquetide
The latest announcement is out from Soligenix ( ($SNGX) ). On August 18, 2025, ...
08-18 21:29
Soligenix shares are trading higher after the company reported better-than-expected Q2 EPS results.
Soligenix shares are trading higher after the company reported better-than-expe...
08-14 23:51
Soligenix Q2 EPS $(0.82) Beats $(0.92) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.92) by 10.87 percent. This is a 37.4 percent increase over losses of $(1.31) per share from the same
08-14 19:39
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
Soligenix Inc. (NASDAQ: SNGX) has been featured in an editorial by NetworkNewsWire (NNW), highlighting its work in advancing treatments for rare diseases, particularly those affecting older adults. The company's HyBryte™ platform, a novel therapy for cutaneous T-cell lymphoma (CTCL), has shown promise, with successful U.S.-based manufacturing of its active ingredient. Soligenix is also advancing other innovative programs, including synthetic hype...
08-07 12:30
